Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 47.58% | 54.78% | 50.34% | 27.31% | 15.32% |
| Total Depreciation and Amortization | -8.80% | -11.26% | -13.30% | -8.55% | -11.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.86% | -93.76% | -85.76% | -59.33% | -51.75% |
| Change in Net Operating Assets | -2,080.30% | -479.74% | -587.60% | -544.53% | -83.98% |
| Cash from Operations | 27.22% | 40.06% | 19.33% | 15.49% | 7.66% |
| Capital Expenditure | -- | 82.76% | 82.76% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -72.22% | 2,100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -81.84% | -100.00% | -92.44% | 95.83% |
| Cash from Investing | -100.00% | -81.64% | -99.82% | -92.36% | 96.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -51.90% | -15.71% | 287.64% | 351.69% | 1,730.14% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 190.70% | -- | -- | -1,570.00% | -3,340.00% |
| Cash from Financing | -9.91% | 19.72% | 383.56% | 349.70% | 1,723.57% |
| Foreign Exchange rate Adjustments | -- | 150.00% | -100.00% | -112.50% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9,945.71% | 83.11% | 90.82% | 36.78% | 99.78% |